Regeneron Pharmaceuticals Inc and Sanofi SA have scaled back their collaboration in immuno-oncology to co-develop just two bispecific compounds, leaving other projects to be pursued independently by the two companies.
The restructuring affects a partnership dating from 2015 which has already yielded one approved product, Libtayo (cemiplimab), for the treatment of advanced cutaneous squamous cell carcinoma. Libtayo was approved by the US Food and Drug Administration in September 2018.